These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31668324)

  • 1. Effectiveness of Nivolumab on Sarcomatoid Malignant Pleural Mesothelioma With Eosinophilia and Eosinophilic Pleural Effusion.
    Yamazoe M; Ozasa H; Kim YH
    J Thorac Oncol; 2019 Nov; 14(11):e251-e253. PubMed ID: 31668324
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
    Quispel-Janssen J; van der Noort V; de Vries JF; Zimmerman M; Lalezari F; Thunnissen E; Monkhorst K; Schouten R; Schunselaar L; Disselhorst M; Klomp H; Hartemink K; Burgers S; Buikhuisen W; Baas P
    J Thorac Oncol; 2018 Oct; 13(10):1569-1576. PubMed ID: 29908324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
    Cerbone L; Delfanti S; Crivellari S; De Angelis AM; Mazzeo L; Proto C; Occhipinti M; Lo Russo G; Dellepiane C; Biello F; Alabiso I; Verderame F; Gauna R; De Simone I; Cuppone F; Petraglia S; Pasello G; Ceresoli GL; Garassino MC; Torri V; Grosso F
    Tumori; 2024 Jun; 110(3):168-173. PubMed ID: 38372045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
    Szulkin A; Otvös R; Hillerdal CO; Celep A; Yousef-Fadhel E; Skribek H; Hjerpe A; Székely L; Dobra K
    BMC Cancer; 2014 Sep; 14():709. PubMed ID: 25253633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
    Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant mesothelioma clinical trial combines immunotherapy drugs.
    Chatwal MS; Tanvetyanon T
    Immunotherapy; 2018 Apr; 10(5):341-344. PubMed ID: 29473471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapsed malignant pleural mesothelioma: An impressive response to Nivolumab monotherapy.
    Costa-Martins S; Vicente I; Valente S
    Pulmonology; 2022; 28(2):142-144. PubMed ID: 34801435
    [No Abstract]   [Full Text] [Related]  

  • 10. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
    Laune Q; Brosseau S
    Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
    [No Abstract]   [Full Text] [Related]  

  • 11. Intrapleural nivolumab in cancer patients with pleural effusion.
    Tsimafeyeu I; Goutnik V; Shrainer I; Kosyrev V; Bondarenko A; Utyashev I
    J Cancer Res Ther; 2024 Apr; 20(3):1036-1038. PubMed ID: 39023613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Serum Mesothelin as an Indicator of Tumor Progression in Routine Clinical Practice of Malignant Pleural Mesothelioma Treatment.
    Vigani A; Pistillo MP; Fontana V; Giannoni U; Rosenberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
    J Thorac Oncol; 2018 Aug; 13(8):e143-e145. PubMed ID: 30049376
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.
    Mundt F; Heidari-Hamedani G; Nilsonne G; Metintas M; Hjerpe A; Dobra K
    Biomed Res Int; 2014; 2014():419853. PubMed ID: 25147801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
    Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
    Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab activity in advanced refractory malignant peritoneal mesothelioma.
    Becker O; Beaulaton C; Masliah-Planchon J; Servois V; Watson S
    Eur J Cancer; 2021 Feb; 144():386-388. PubMed ID: 33358840
    [No Abstract]   [Full Text] [Related]  

  • 16. Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
    Nakamura A; Kondo N; Nakamichi T; Kuroda A; Hashimoto M; Matsumoto S; Yokoi T; Kuribayashi K; Kijima T; Hasegawa S
    Jpn J Clin Oncol; 2020 Aug; 50(8):920-925. PubMed ID: 32463095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab for the treatment of unresectable pleural mesothelioma.
    Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
    Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel therapies for malignant pleural mesothelioma.
    Scherpereel A; Wallyn F; Albelda SM; Munck C
    Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
    Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
    Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishing mesothelioma patient-derived organoid models from malignant pleural effusions.
    Hocking AJ; Mortimer LA; Farrall AL; Russell PA; Klebe S
    Lung Cancer; 2024 May; 191():107542. PubMed ID: 38555809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.